Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LYRA NASDAQ:PFSA NASDAQ:SSKN NASDAQ:XAGE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLYRALyra Therapeutics$0.69$0.70$0.31▼$14.88$1.23M0.759,737 shs1,377 shsPFSAProfusa$0.25+15.5%$0.49$0.21▼$180.00$1.03M0.35360,397 shs2.99 million shsSSKNStrata Skin Sciences$0.14-6.9%$0.14$0.11▼$3.86$817K-0.06243,264 shs6,837 shsXAGELongevity Health$0.32+24.1%$0.33$0.23▼$8.27$577K0.382,854 shs2,249 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLYRALyra Therapeutics+6.15%-13.75%-1.43%+55.06%-93.91%PFSAProfusa-6.90%-20.12%-50.58%-71.05%+21,999,900.00%SSKNStrata Skin Sciences+23.14%+23.14%+22.13%-43.77%-93.23%XAGELongevity Health0.00%-1.64%-33.67%-27.24%+30,509,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLYRALyra Therapeutics$0.69$0.70$0.31▼$14.88$1.23M0.759,737 shs1,377 shsPFSAProfusa$0.25+15.5%$0.49$0.21▼$180.00$1.03M0.35360,397 shs2.99 million shsSSKNStrata Skin Sciences$0.14-6.9%$0.14$0.11▼$3.86$817K-0.06243,264 shs6,837 shsXAGELongevity Health$0.32+24.1%$0.33$0.23▼$8.27$577K0.382,854 shs2,249 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLYRALyra Therapeutics+6.15%-13.75%-1.43%+55.06%-93.91%PFSAProfusa-6.90%-20.12%-50.58%-71.05%+21,999,900.00%SSKNStrata Skin Sciences+23.14%+23.14%+22.13%-43.77%-93.23%XAGELongevity Health0.00%-1.64%-33.67%-27.24%+30,509,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLYRALyra Therapeutics 1.50ReduceN/AN/APFSAProfusa 1.00SellN/AN/ASSKNStrata Skin Sciences 1.00SellN/AN/AXAGELongevity Health 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest XAGE, LYRA, PFSA, and SSKN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2026PFSAProfusa Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLYRALyra Therapeutics$600K2.04N/AN/A$8.86 per share0.08PFSAProfusa$100K11.85N/AN/A($21.69) per share-0.01SSKNStrata Skin Sciences$30.98M0.03N/AN/A$1.19 per share0.12XAGELongevity Health$1.05M0.55N/AN/A($6.77) per share-0.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLYRALyra Therapeutics-$93.43M-$19.15N/AN/AN/A-5,491.17%-1,010.91%-58.92%N/APFSAProfusa-$35.82M-$169.72N/AN/AN/AN/AN/A-1,348.07%N/ASSKNStrata Skin Sciences-$10.09M-$1.41N/AN/AN/A-35.64%-476.73%-33.49%8/19/2026 (Estimated)XAGELongevity Health-$10.37M-$4.29N/AN/AN/A-682.67%N/A-261.90%N/ALatest XAGE, LYRA, PFSA, and SSKN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026PFSAProfusaN/A-$2.05N/A-$2.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthLYRALyra TherapeuticsN/AN/AN/AN/AN/APFSAProfusaN/AN/AN/AN/AN/ASSKNStrata Skin SciencesN/AN/AN/AN/AN/AXAGELongevity HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLYRALyra TherapeuticsN/A2.432.43PFSAProfusaN/A0.020.02SSKNStrata Skin Sciences10.220.950.75XAGELongevity HealthN/A0.470.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLYRALyra Therapeutics95.62%PFSAProfusa9.81%SSKNStrata Skin Sciences32.43%XAGELongevity Health24.22%Insider OwnershipCompanyInsider OwnershipLYRALyra Therapeutics3.25%PFSAProfusa0.76%SSKNStrata Skin Sciences40.92%XAGELongevity Health29.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLYRALyra Therapeutics501.78 million1.72 millionNo DataPFSAProfusa24.66 million4.63 millionN/ASSKNStrata Skin Sciences1205.89 million3.48 millionNot OptionableXAGELongevity Health141.78 million1.27 millionN/AXAGE, LYRA, PFSA, and SSKN HeadlinesRecent News About These CompaniesLongevity Health Announces Routine Board Member ResignationJune 4, 2026 | tipranks.comHead to Head Contrast: Longevity Health (NASDAQ:XAGE) & Biosig Technologies (NASDAQ:STEX)March 27, 2026 | defenseworld.netDLongevity Health Holdings Closes Strategic Investment and Appoints Ram Ajjarapu as Chairman and CEO to Drive Acquisition-Focused GrowthMarch 17, 2026 | globenewswire.comLongevity Health Holdings Ends Merger with True HealthDecember 12, 2025 | tipranks.comWhy Longevity Health Stock Is Skyrocketing TodayJuly 15, 2025 | benzinga.comWhy Longevity Health Stock Is Skyrocketing TodayJuly 15, 2025 | benzinga.comWhy did XAGE Stock Surge in Today’s Premarket Trading?July 15, 2025 | tokenist.comTLongevity Health Holdings, Inc.: Longevity Health Holdings Announces Merger with THPlasma and Termination of 20/20 BioLabs TransactionJuly 15, 2025 | finanznachrichten.deLongevity Health Holdings to Merge With True HealthJuly 15, 2025 | marketwatch.comLongevity Health stock soars after merger with THPlasma in all-stock dealJuly 15, 2025 | investing.comLongevity Health Holdings Announces Merger with THPlasma and Termination of 20/20 BioLabs TransactionJuly 14, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXAGE, LYRA, PFSA, and SSKN Company DescriptionsLyra Therapeutics NASDAQ:LYRA$0.69 0.00 (0.00%) As of 06/16/2026 03:44 PM EasternLyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.Profusa NASDAQ:PFSA$0.25 +0.03 (+15.55%) Closing price 03:59 PM EasternExtended Trading$0.28 +0.03 (+12.12%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.Strata Skin Sciences NASDAQ:SSKN$0.14 -0.01 (-6.91%) As of 03:17 PM EasternSTRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. The company products include XTRAC and Pharos excimer lasers, and VTRAC lamp systems for the treatment systems that are used for the treatment of psoriasis, vitiligo, and other skin conditions. It also offers TheraClear Acne Therapy System for the treatment of mild to moderate inflammatory, comedonal, and pustular acne. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.Longevity Health NASDAQ:XAGE$0.32 +0.06 (+24.05%) As of 03:20 PM EasternCarmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave Insider Sales Look Big, But Should Investors Worry? Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves Meta and Cloud Computing: Real Potential, or a Shot in the Dark? Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Fox Captures The Living Room With $22B Roku Buy Dave & Buster’s Q1 Miss Raises the Stakes for Its Turnaround Plan Microsoft’s Xbox Problem Is Bigger Than a Console War Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
